Market Overview - The Hang Seng Index closed at 26,999.8 points, up 0.6%, while the Hang Seng China Enterprises Index rose 0.3% to 9,315.6 points[1] - Trading volume increased to HKD 340.4 billion, an 8.0% rise from the previous day's HKD 315.2 billion, indicating a potential portfolio reallocation by investors[1] - Non-essential consumer, healthcare, and materials sectors saw increases of 2.2%, 1.3%, and 1.0% respectively, while utilities, industrials, and financials declined by 0.4%, 0.2%, and 0.2%[1] Stock Performance - Alibaba Health (241 HK) and Haidilao (6862 HK) led the gainers, rising 19.0% and 9.2% respectively[1] - Ctrip Group (9961 HK) and Xinyi Glass (868 HK) were the biggest losers, falling 6.5% and 3.9% respectively[1] Regulatory Developments - Ctrip Group is under investigation for alleged monopolistic practices, which may benefit the industry by ensuring better protection for businesses and consumers in the long run[1] - The China Securities Regulatory Commission approved an increase in the minimum financing margin ratio from 80% to 100%, aimed at reducing leverage and promoting market stability[1] Macro Dynamics - China's exports in December increased by 6.6% year-on-year, surpassing November's 5.9% and market expectations of 3.0%[3] - U.S. retail sales rose by 0.6% in November, better than October's decline of 0.1% and exceeding the forecast of 0.4%[3] Industry Insights - Macau's gaming revenue is projected to grow by 15%-20% year-on-year in January, with a strong start in the first week showing an 18% increase[4] - China Biologic Products (1177 HK) announced a maximum acquisition price of RMB 1.2 billion for Hejiya, focusing on innovative drug development in metabolic diseases[5] - The healthcare index rose by 1.3%, with China Biologic Products increasing by 2.9% following the acquisition announcement[5]
媒体报导，近日市场监管总局按照《中华人民共和国反垄断法》，对携程集团涉嫌滥用市场支配地位实施垄断行为立案
ZHONGTAI INTERNATIONAL SECURITIES·2026-01-15 04:03